Calmark signs distributor agreement for India regarding COVID19-LDH

Report this content

Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company r2 Hemostasis Diagnostics India Private Ltd regarding marketing and sales of the Calmark POC - Covid platform in the Indian market. 

Since March, India has reported a dramatic surge in infections, peaking at approximately 400,000 confirmed new COVID-19 cases per day in early May. The prevailing situation is putting a heavy strain on the healthcare system, which in many places is struggling to meet the need for hosppital beds, equipment and pharmaceuticals. Calmark POC - Covid is a platform for rapid testing of the LDH biomarker, which is an important factor in the assessment of the level of care that will be needed for each patient.

The company r2 Hemostasis Diagnostics India Private Ltd is an expert in coagulation and is active throughout India and in neighbouring countries. The reputable company also operates in other areas, including pharma and life sciences research.

“I am delighted and very, very pleased with today’s agreement,” says Magdalena Tharaldsen, Director International Business Development at Calmark. “Our product will now be registered in India, a process which will be managed by r2 Hemostasis Diagnostics. We will send over the first product sampes shortly.”

Calmark POC - Covid is a platform consisting of an instrument and a test cassette for measurement of the lactate dehydrogenase (LDH) biomarker in the blood of COVID-19 patients. Elevated levels of LDH are associated with a higher risk of severe disease and death in COVID-19 patients. The platform can be used in, e.g., emergency rooms and hospital wards to assess the required level of care.


Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.


This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-06-2021 19:00 CET.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at  


Documents & Links